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Abstract
Background: The incidence, manifestations, outcome and clinical predictors of paradoxical TB-IRIS in patients with HIV and
culture confirmed pulmonary tuberculosis (PTB) in India have not been studied prospectively.
Methods: HIV+ patients with culture confirmed PTB started on anti-tuberculosis therapy (ATT) were followed prospectively
after anti-retroviral therapy (ART) initiation. Established criteria for IRIS diagnosis were used including decline in plasma HIV
RNA at IRIS event. Pre-ART plasma levels of interleukin (IL)-6 and C-reactive protein (CRP) were measured. Univariate and
multivariate logistic regression models were used to evaluate associations between baseline variables and IRIS.
Results: Of 57 patients enrolled, 48 had complete follow up data. Median ATT-ART interval was 28 days (interquartile range,
IQR 14–47). IRIS events occurred in 26 patients (54.2%) at a median of 11 days (IQR: 7–16) after ART initiation. Corticosteroids
were required for treatment of most IRIS events that resolved within a median of 13 days (IQR: 9–23). Two patients died due
to CNS TB-IRIS. Lower CD4+ T-cell counts, higher plasma HIV RNA levels, lower CD4/CD8 ratio, lower hemoglobin, shorter
ATT to ART interval, extra-pulmonary or miliary TB and higher plasma IL-6 and CRP levels at baseline were associated with
paradoxical TB-IRIS in the univariate analysis. Shorter ATT to ART interval, lower hemoglobin and higher IL-6 and CRP levels
remained significant in the multivariate analysis.
Conclusion: Paradoxical TB–IRIS frequently complicates HIV-TB therapy in India. IL-6 and CRP may assist in predicting IRIS
events and serve as potential targets for immune interventions.
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Introduction
Tuberculosis-associated immune reconstitution inflammatory
syndrome (TB-IRIS) is the paradoxical worsening of clinical
symptoms, signs and radiological features of TB upon initiation of
antiretroviral therapy (ART) after a temporal improvement with
anti-tuberculosis therapy (ATT) [1]. This clinical scenario
develops despite successful suppression of HIV viremia accompa-
nied by increased CD4+ T-cell counts in the blood [1–3].
Although such paradoxical reactions have been described in
HIV seronegative persons infected with TB [4–6], they are far
more common in HIV-TB co-infection, with a reported incidence
between 8–43% [7,8]. The clinical manifestations range from
fever, tachycardia and minor lymph node enlargement to severe
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forms manifesting as respiratory distress or neurological deterio-
ration [2]. The pathogenesis of IRIS remains unclear; both
antigen-reactive T cells and innate responses have been implicated
[9,10]. The most common predisposing factors for IRIS are pre-
ART low CD4+ T lymphocyte counts and pre-existing opportu-
nistic infection (OI) or cancer [1]. Treatment of TB before
administering ART decreases the risk of IRIS by minimizing the
microbial burden at the time of ART-driven immune reconstitu-
tion [11]. As findings from large prospective studies and clinical
trials have demonstrated that delaying ART can result in
increased overall mortality risk associated with AIDS [2,4,7,12–
14], new guidelines recommend early ART initiation in patients
with tuberculosis and severe CD4+ T-cell depletion [15]. Thus, it
is expected that the IRIS burden will significantly increase in
countries with high incidence of TB-HIV co-infection as these
guidelines are implemented. Understanding the risk factors and
potential biomarkers may help to identify patients at very high risk
for IRIS before initiation of ART who might benefit from closer
clinical and laboratory monitoring and earlier interventions [16].
Within many other candidate biomarkers, C-reactive protein
(CRP) has been systematically described as a very sensitive marker
of inflammation and for this reason it has been included in diverse
prospective investigations in HIV-infected populations. Several
clinical studies have suggested pre-ART levels of CRP can serve as
an important biomarker for IRIS and mortality [17,18]. IL-6 is a
cytokine directly linked to CRP and with a critical role in innate
immunity against M. tuberculosis [19]. Previous studies have also
shown increased expression of IL-6 transcripts, secretion in vitro
and serum levels in HIV+ individuals developing TB-IRIS by
comparison with those not developing IRIS [20]. In addition, IL-6
was one of the cytokines that displayed dramatic reduction in the
plasma levels in TB-IRIS patients treated with prednisone [21].
In this prospective study we evaluated the incidence and risk
factors of paradoxical TB-IRIS among newly diagnosed culture
positive, non–rifampicin resistant pulmonary TB patients with
HIV who were ART- naı¨ve and were followed after ART
initiation. In addition, we evaluated baseline plasma levels of CRP
(an easily accessible laboratory measurement of inflammation) and
IL-6 (a cytokine known to induce CRP production) to assess their
potential role as predictors of IRIS [18,20,22].
Methods
Study Design
This TB-IRIS sub-study was nested within a randomized
controlled clinical trial (NCT 933790) at the National Institute for
Research in Tuberculosis (NIRT), Chennai, India, enrolling HIV
patients with newly diagnosed sputum culture confirmed pulmo-
nary TB [23]. The parent randomized trial (ongoing at the time of
this report) is comparing daily vs. intermittent ATT regimen in
HIV+ patients with pulmonary tuberculosis. The present study
was designed to enroll subjects during the first two years of the
parent study. Eligible participants for the sub-study had to be
above 18 years of age, HIV+ with pulmonary TB confirmed by
sputum cultures, harboring rifampicin sensitive Mycobacterium
tuberculosis at baseline, ART naı¨ve, willing to take drugs under
supervision, and willing to sign informed consent. Baseline
investigations included 2 rapid HIV tests followed by ELISA,
hepatitis B and C serology. Complete blood count (automated
hematology analyzer ABX, France), CD4+ T-cell count (FACS
count flow cytometer, Becton Dickinson, USA), plasma HIV viral
load (Roche Amplicor automated viral load monitor, Germany),
liver and renal function tests, and random plasma sugar
(automated analyzer, Olympus Corporation, Tokyo, Japan) were
performed at enrollment. A posteroanterior (PA) chest X-ray
(CXR) was performed at baseline and at IRIS event or after 1–2
months of ART in the non-IRIS group per standard clinical
practice and was evaluated by two independent experienced
readers from a group of five physicians (CC, KS, MA, RK, RR).
Three sputum smears were examined by fluorescence microscopy,
processed by the modified Petroff’s method and cultured on
Lowenstein-Jensen medium (LJ), with species identification and
drug susceptibility testing done at baseline and every month until
completion of ATT. Positive cultures of Mycobacterium tuberculosis
were graded as 1+ (20–100 colonies), 2+ (more than 100 discrete
colonies) and 3+ (more than 100 colonies forming a confluent
mass). For growth up to 19 colonies, exact number of colonies was
recorded as previously described [24].
Treatment of pulmonary TB consisted of four drugs: ethambu-
tol (800/1200 mg), rifampicin (450/600 mg), pyrazinamide
(1000/1500 mg) and isoniazid (INH) (300/600 mg) for 2 months
(intensive phase) followed by INH (300/600 mg) and rifampicin
(450/600 mg) for 4 months (continuation phase) given daily or
thrice a week, according to the randomization arm in the clinical
trial. In regimen 1, drugs were given daily throughout. In regimen
2, the drugs were administered daily in the intensive phase and
thrice weekly in the continuation phase, while in regimen 3, ATT
was given thrice weekly throughout. All doses were directly
observed. ART was started within the intensive phase of ATT,
according to Indian national guidelines, after patients were
stabilized without overt toxicity to ATT. The ART regimen
consisted of either Stavudine (30/40 mg) or Zidovudine (300 mg)
given along with Lamivudine (150 mg) twice per day and
Efavirenz (600 mg/day) [23]. Patients were hospitalized for
ART initiation and were discharged within two weeks. All patients
were followed up for 18 months following the start of ATT.
Ethics Statement
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consents were obtained from all participants before
enrolling into the sub-study. This study was approved by the
Scientific Advisory Committee and Institutional Ethics Committee
of Tuberculosis Research Centre, Chennai.
Diagnosis of IRIS Events
Patients who developed symptoms and signs suggestive of
paradoxical IRIS were clinically assessed. CXR and other
appropriate investigations were performed if symptoms persisted
for at least three days. Blood smear samples were screened for
Plasmodium sp. and urine cultures were routinely performed to work
up febrile episodes. A suspected diagnosis of IRIS was made by a
panel of independent physicians (CC, KS, RN, PM, RK) who
reviewed the patient’s history, radiographs and physical examina-
tion based on case definition guidelines from The International
Network for the Study of HIV-associated IRIS (INSHI) [1]. The
identified cases of suspected IRIS were adjudicated by a panel of
study clinicians (GN, BBA, BOP, IS, SoS) that also required a
decline of at least 0.5 log10 copies/mL of the plasma HIV viral
load with/without an associated increase in CD4+ T-cell count for
definite IRIS. Enlarged lymph nodes were evaluated with fine
needle aspiration or surgical drainage with cultures for M.
tuberculosis and also for gram positive and negative bacteria.
Baseline investigations were repeated at IRIS event in the IRIS
group and after 1–2 months of ART in those who were uneventful
after ART initiation.
TB-IRIS in HIV Patients with Culture Positive TB
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Plasma Biomarker Measurements
Levels of IL-6 (R&D Systems, Minneapolis, MN), and CRP
(eBioscience, San Diego, CA) were assessed in cryopreserved
plasma samples maintained at 280uC. The limits of detection
were: IL-6, 0.11 pg/mL; CRP, 0.15 mg/L.
Statistical Analysis
Median values with interquartile ranges (IQR) or frequencies of
baseline variables were compared using the Mann-Whitney or
Chi-square tests respectively. Multinomial logistic regression was
used to evaluate the influence of potential risk factors on the
occurrence of IRIS (response variable) including the following
independent variables: age, gender, weight, hemoglobin, hemat-
ocrit, sputum culture grade, presence of extra-pulmonary or
military TB, days to ART initiation, plasma HIV RNA levels,
CD4+ T-cell count, IL-6 and CRP. For IL-6 and CRP, the relative
risk (RR) shown is per standard deviation after log10 transforma-
tion of each biomarker. The threshold values of IL-6 or CRP
plasma levels, which discriminated patients who developed IRIS
during the study follow up from those who did not with a high
likelihood ratio, were estimated using Receive Operator Charac-
teristics (ROC) curve analyses. The correlation between IL-6 and
CRP was assessed using the Spearman test.
Results
Baseline Characteristics of the Study Participants
From December of 2009 to November of 2011, a total of 57
HIV positive patients with newly diagnosed culture confirmed
PTB (45 males: 12 females), who were ATT and ART naı¨ve, were
enrolled in the parent study and 48 of those were included in the
TB-IRIS sub-study. Nine patients (18.7%) were excluded due to
death prior to ART initiation (n = 3), non-adherence (n = 2), initial
culture negative for M. tuberculosis (n = 2) and change of ATT
before introduction of ART (n = 2). The baseline characteristics of
the individuals enrolled in the study are shown in Table 1. Pre-
ATT sputum cultures grew Mycobacterium tuberculosis susceptible to
all first line drugs, except two patients who had pretreatment INH
resistance.
Incidence of IRIS Events
Twenty-six out of 48 patients (54%) experienced IRIS events.
The pre-ART characteristics of IRIS vs. non-IRIS are shown in
Table 2. The two groups were similar with respect to gender, age,
body weight and CD8+ T-cell counts and levels of ALT and AST
at baseline. Pre-ART hemoglobin was lower in those individuals
developing IRIS (median 8.5 vs. 10.1g/dL, P = 0.007), as was the
hematocrit (median 25.5 vs. 29.2 P = 0.023). In addition,
individuals who experienced IRIS during follow up had signifi-
cantly lower CD4+ T-cell counts than those who did not (median
93 vs. 459, P = 0.005). The median time to ART initiation was 20
days (IQR: 14–30) in IRIS and 43 days (IQR: 23–68) in non-IRIS
(P = 0.002). There was no statistically significant difference in the
incidence of IRIS between the ATT randomization groups
(P = 0.197).
The IRIS events occurred at a median of 11 days (IQR: 7–16)
after ART initiation. Five patients (19.2%) had two episodes and
two (7.7%) had three episodes of IRIS. Two patients experienced
worsening of symptoms similar to IRIS with ATT itself (prior to
ART administration). These patients had recurrence of these
symptoms and recrudescence of lesions in the same site in a more
pronounced fashion after initiation of ART which were adjudi-
cated as IRIS events (one case of central nervous system [CNS]
IRIS and one with pleurisy). The incidence of TB-IRIS in patients
with CD4+ T-cell counts of,50, 50–99, 100–199 and$200 cells/
mL was 72%, 63%, 52% and 20% respectively.
The overall risk of IRIS within 3 months of ART initiation was
associated with a shorter (,30 days) interval between ATT and
ART and lower levels of hemoglobin (Figure 1). The unadjusted
univariate associations between CD4+ T-cell counts, higher HIV
RNA levels and the presence of extra-pulmonary or miliary TB at
baseline were not significant after adjustment for potential
confounding variables (Figure 1).
Clinical Features and Manifestations of Paradoxical IRIS
Fever with rigor or chills was the predominant presenting
symptom of IRIS occurring in all except one patient who
presented with generalized tonic clonic seizures and had a brain
Table 1. Baseline characteristics of the study participants.
Characteristic
Study population
(N=48)
Male gender 38 (79.2)
Age, median years (IQR) 36 (30–42)
Weight, median Kg (IQR) 41.0 (36.0–47.5)
Time to ART, median days (IQR) 28 (14–47)
Hematology
Hemoglobin, median g/dL (IQR) 9.2 (8.0–10.5)
Hematocrit, median % (IQR) 27.3 (23.3–31.0)
RBC count, median6106/mL (IQR) 3.5 (3.0–4.1)
CD4+ T-cells/mL, median (IQR) 123 (58–187)
CD8+ T-cell/mL, median (IQR) 605 (312–958)
CD4/CD8 ratio, median (IQR) 0.18 (0.09–0.35)
HIV RNA, median log10 copies/mL plasma (IQR) 5.6 (5.2–5.9)
Plasma biochemistry
ALT, median IU/L (IQR) 30.5 (14.0–48.7)
AST, median IU/L (IQR) 39.0 (25.0–68.5)
TB evaluation
Sputum smear grade
1+ 21 (43.7)
2+ 17 (35.5)
3+ 10 (20.8)
Sputum culture grade
1+ 9 (18.7)
2+ 15 (31.3)
3+ 24 (50.0)
Number of chest X-ray zones, median (IQR) 3 (2–5)
Presence of EPTB site 26 (54.2)
Presence of miliary TB 15 (31.3)
ATT regimen*
Regimen 1 18 (37.5)
Regimen 2 12 (25.0)
Regimen 3 18 (37.5)
NOTE. Data represent no. (%) of participants unless otherwise specified. ALT,
alanine transaminase; AST, aspartate aminotransferase; ATT, anti-tuberculous
treatment; EPTB, extra-pulmonary tuberculosis; IQR, interquartile range; RBC,
red blood cell; TB, tuberculosis.
*The ATT regimens differentiated according to the frequency of drug
administration (see Methods for full discrimination of the regimens).
doi:10.1371/journal.pone.0063541.t001
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tuberculoma. None of the patients had M. tuberculosis growth in
culture at the time of the suspected IRIS event. Worsening
lymphadenopathy was the next most common manifestation
occurring in 76% (20/26) of patients. Three had Broch’s
syndrome (middle lobe collapse consolidation caused by a
constriction ring of enlarged right hilar nodes). CNS IRIS was
present in four patients, ending fatally in two of them. Radiological
deterioration of the CXR was seen in 23/26 patients. Of the 26
patients who experienced IRIS, 15 (57%) had exaggeration,
extension or enlargement of pre-existing lesions, two (8%) had
appearance of new lesions and nine (35%) had both.
Plasma IL-6 and CRP as Candidate Biomarkers for TB-IRIS
Plasma levels of IL-6 and CRP assessed prior to ART initiation
were elevated in the patients who experienced IRIS events
compared to those who did not (P = 0.015 and P = 0.006,
respectively, Figure 2A). The number of persons having levels of
IL-6 and CRP simultaneously above the median values of the
study population was higher in the group of patients that
developed IRIS (14/26, 53.8%) than in those who did not (3/
22, 13.6%) (Fisher’s exact test P = 0.023; Figure 2B). CRP and IL-
6 displayed similar power to discriminate patients that would
experience IRIS from those with uneventful follow up (area under
the curves from ROC analysis: IL-6 0.71, P = 0.015; CRP 0.73,
P = 0.006); however, the combination of the assays resulted in a
sensitivity 12% higher than IL-6 and 16% higher than CRP alone
for detection of IRIS (sensitivities: IL-6+CRP = 92%; IL-6 = 80%;
CRP = 76%). The univariate associations between IL-6 or CRP
and the risk for IRIS persisted after adjustments for age, gender,
weight, hemoglobin, hematocrit, sputum culture grade, presence
of extra pulmonary or miliary TB, days to ART initiation, plasma
HIV RNA levels and CD4+ T-cell count (Figure 2C).
Management and Outcome of IRIS
Patients experiencing IRIS were treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) for the first 3–5 days. Prednisolone
(0.5–1 mg/Kg/day) was administered for a median of 4 weeks in
21/26 patients who had suboptimal response or persistence of
symptoms with NSAIDs. Six patients with more severe manifes-
tations (one with tuberculoma, two with meningitis, and three with
significant mediastinal and abdominal adenopathy) required
higher doses and longer acting (dexamethasone) or parenteral
corticosteroids (methylprednisolone) for 1–2 weeks followed by
oral prednisolone at 1–2 mg/Kg of body weight. The median time
to resolution or significant improvement of symptoms was 13 days
(IQR: 9–23). ART was not interrupted in any patient due to
Table 2. Baseline characteristics of the study population stratified by IRIS status.
Characteristic IRIS (N=26) Non-IRIS (N=22) P-value
Male gender 20 (76.9%) 18 (81.8%) 0.735
Age, median years (IQR) 36 (27–46) 37 (31–40) 0.967
Weight, median Kg (IQR) 42.0 (36.0–48) 40.5 (35.7–46.5) 0.732
Time to ART, median days (IQR) 20 (14–30) 43 (23–68) ,0.001
Hematology
Hemoglobin, median g/dL (IQR) 8.5 (7.1–10.2) 10.1 (9.0–11.3) 0.007
Hematocrit, median % (IQR) 25.5 (20.4–30.6) 29.2 (25.9–33.2) 0.023
RBC count, median6106/mL (IQR) 3.47 (2.8–3.8) 3.9 (3.2–4.1) 0.087
CD4+ T-cells/mL, median (IQR) 93 (39–135) 156 (89–264) 0.005
CD8+ T-cell/mL, median (IQR) 765 (311–1095) 459 (297–727) 0.109
CD4/CD8 ratio, median (IQR) 0.09 (0.05–0.18) 0.34 (0.21–0.47) ,0.001
HIV RNA, median log10 copies/mL plasma (IQR) 5.9 (5.4–5.9) 5.3 (4.5–5.6) ,0.001
Plasma biochemistry
ALT, median IU/L (IQR) 30.5 (14.0–52.2) 30.5 (13.5–45.7) 0.868
AST, median IU/L (IQR) 54.5 (30.5–91.7) 35.0 (22.7–62.2) 0.102
TB evaluation
Sputum smear grade 0.515
1+ 13 (50%) 8 (36.4%)
2+ 9 (34.6%) 8 (36.4%)
3+ 4 (15.4%) 6 (27.2%)
Sputum culture grade 0.002
1+ 6 (23.0%) 3 (13.7%)
2+ 10 (38.5%) 5 (22.7%)
3+ 10 (38.5%) 14 (63.6%)
Number of chest X-ray zones, median (IQR) 3 (2–5) 3 (2–5) 0.824
Presence of EPTB site 19 (73.1%) 7 (31.8%) 0.004
Presence of miliary TB 12 (46.1%) 3 (13.6%) 0.012
NOTE. Data represent no. (%) of participants unless otherwise specified. ALT, alanine transaminase; AST, aspartate aminotransferase; ATT, anti-tuberculous treatment;
EPTB, extra-pulmonary tuberculosis; IQR, interquartile range; RBC, red blood cell; TB, tuberculosis.
doi:10.1371/journal.pone.0063541.t002
TB-IRIS in HIV Patients with Culture Positive TB
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e63541
Figure 1. Associations between pre-ART clinical and laboratory characteristics with subsequent TB-IRIS events. Baseline (pre-ART)
characteristics significantly different between patients that developed TB-IRIS events in the follow up and those who did not were assessed to test
associations with risk for IRIS in univariate and multinomial logistic models. Relative risks (RR) are for values below or above the threshold levels
displayed, which were estimated close to median values for the overall study population. Adjustment was performed for all variables presented and
also included age and gender. 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0063541.g001
Figure 2. Pre-ART plasma levels of IL-6 or CRP distiguish individuals at higher risk for TB-IRIS. (A) Pre-ART plasma concentrations of IL-6
(left panel) and CRP (right panel) were compared between individuals who developed TB-IRIS during study follow up and those who did not using
the Mann-Whitney test. (B) Correlation between IL-6 and CRP values was tested in both groups of patients using the Spearman test. In (B), dotted
lines represent the median pre-ART values of IL-6 or CRP in the entire study population. Gray areas highlight those patients displaying values for both
biomarkers above their respective median values within the study population. (C) The associations between systemic levels of IL-6 and CRP with risk
for subsequent TB-IRIS were assessed by univariate and multivariate models. Relative risks (RR) are per standard deviation increase after log10
transformation. RR were adjusted for baseline age, gender, weight, hemoglobin, hematocrit, sputum culture grade, presence of extra pulmonary TB,
presence of miliary TB, days to ART initiation, plasma HIV RNA levels and CD4+ T-cell count. CI, confidence interval.
doi:10.1371/journal.pone.0063541.g002
TB-IRIS in HIV Patients with Culture Positive TB
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e63541
occurrence of IRIS. Two patients died with CNS IRIS (mortality
7.7%). There was one death at month 5 after ART initiation
(mortality of 4.5%) in the non-IRIS group, and the cause of death
was unclear.
Discussion
In this study we evaluated prospectively a group of newly
diagnosed, sputum culture confirmed, pulmonary TB patients with
HIV, who were treatment naı¨ve for both TB and HIV, and
followed them after initiation of supervised ATT and ART for
emergence of paradoxical TB-IRIS. The diagnosis of IRIS was
established taking into account the clinical signs and symptoms
including a reduction in HIV viral load, and all cases had AFB
culture negativity at the time of the IRIS event. Our findings
indicate that more severe immunodeficiency and higher myco-
bacterial antigen load (extra-pulmonary disease and shorter
interval between ATT and ART initiation) along with higher
levels of IL-6 and CRP prior to ART initiation are strongly
associated with paradoxical TB-IRIS.
The incidence of paradoxical TB-IRIS in this study was high,
with over half of the participants developing paradoxical reactions.
This could be due to the overall shorter interval between starting
ATT to ART initiation, the lower median CD4+ T-cell count and
the fact that all patients had confirmed (culture-positive) pulmo-
nary TB cases. In addition, closer monitoring and hospitalization
for safe initiation of ART made earlier recognition and prompt
intervention possible. The closer monitoring and prompt initiation
of corticosteroids in cases of IRIS diagnosis might helped an early
resolution of signs and symptoms of IRIS, and maybe for this
reason the average duration of the IRIS events was shorter than in
other studies [4,11,16]. Previous studies from the same TB
endemic area had shown an incidence of IRIS of 2% among HIV-
TB co-infected patients upon initiation of ATT alone, at the pre-
ART era [25], and of 21% when ART was started at 8 weeks of
ATT [26]. A more recent study from our group investigating
patients with CD4+ T-cell counts raging up to 63 cells/mL revealed
an incidence of 35%, and the IRIS cases were more common in
patients with a prior history of TB [27]. In the present study, the
median time to ART was only 5 weeks and could have contributed
to the higher incidence. Another factor that might have influenced
the IRIS incidence was the fact that all the patients had positive
sputum cultures for M. tuberculosis, whereas in previous studies in
the same endemic region approximately 70% of cases were culture
confirmed. In addition, there was a higher proportion of extra-
pulmonary TB, 52% of the current study participants, contrasting
with lower than 25% detected in previous studies [25,26]. Thus,
our findings argue that pre-ART mycobacterial burden is a critical
predisposing factor associated with increased risk of IRIS in HIV/
TB co-infection.
Several recently published randomized controlled studies
including SAPIT, CAMELIA and STRIDE, have shown that
ART should be started within the first two weeks of ATT in
severely immunocompromised HIV/TB co-infected patients [12–
14,28], as this strategy can reduce all-cause mortality despite the
higher incidence of paradoxical TB-IRIS. These results do not
apply in cases of TB meningitis, as CNS IRIS can be fatal [29].
The most striking results on the impact of early ART initiation on
IRIS incidence came from the CAMELIA study, where the
hazards ratio of developing IRIS was double in the study arm that
had immediate ART initiation than the group of individuals in
which ART was delayed, with 10% of the total mortality
attributable to IRIS [14]. However, subjects enrolled in the
CAMELIA study were sicker and had a median CD4+ T-cell
count of 25 cells/mL, significantly lower than in our study. In
ACTG 5221 study (STRIDE), the median CD4+ T-cell count at
entry was 77 cells/mL but only 46% of participants had culture-
confirmed TB [28]. The incidence of paradoxical TB-IRIS was
11% when ART was started at 2 weeks of ATT compared to 5%
when it was started at 8 weeks. In patients with CD4+ T cell counts
of .50 cells/mL, delaying ART for 8 weeks did not increase risk
but showed a definite reduction in IRIS incidence [28]. Consistent
with these findings, in our study early ART initiation was a key
predisposing factor for TB-IRIS, probably also pointing to a
higher antigen burden.
Fevers with rigors or chills were the predominant symptoms of
IRIS, along with lymphadenopathy (both cervical and intratho-
racic). Previous studies in other populations have shown similar
findings [4,30–32] and altogether highlight the importance of
lymphadenopathy as a clinical manifestation of paradoxical TB-
IRIS. A recent report showed 82% of IRIS events occurring in
pre-existing sites and 18% occurring at new sites [33] that are
comparable to those reported in our study. The preferential
occurrence of IRIS related pathology in sites of ongoing
mycobacterial infection reinforces the hypothesis that the immu-
nopathogenesis of this disease involves immune restoration and
inflammatory burst in sites overwhelmed by M. tuberculosis
antigens. Patients were treated with low doses of oral corticoste-
roids, which were well tolerated and efficacious except in six cases
that initially required parenteral steroids. Our results are in
agreement with a recent randomized clinical trial in South Africa
[16] comparing prednisone and placebo that demonstrated an
unequivocal benefit of earlier prednisone administration in cases of
suspected IRIS in shortening hospital stay and reducing proce-
dures.
Drug resistant TB stands high in the list of differential diagnoses
to consider in cases of persisting clinical deterioration despite ART
initiation [4,34]. Drug resistant TB cases can have an initial
improvement on ATT due to the ‘‘fall’’ of drug susceptible strains
with subsequent recrudescence of symptoms and signs caused by
the ‘‘rise’’ of resistant strains – the so called ‘‘fall and rise’’
phenomenon [35]. Use of corticosteroids in this scenario could
potentially have a detrimental effect on prognosis. Hence, ruling
out drug resistance, as was done in our study, becomes a critical
step before IRIS diagnosis is established, especially when
corticosteroid use is contemplated. The introduction of line probe
assay in the TB programme in India has helped in diagnosing
initial rifampicin resistance [36].
Paradoxical TB-IRIS events can cause significant morbidity and
mortality as well as increased expenditure of resources to evaluate
and treat patients, making prediction essential for better clinical
management. In our cohort, more advanced immunosuppression
manifested by lower CD4+ T-cell counts, higher HIV RNA levels,
and lower CD4/CD8 ratio, in addition to higher mycobacterial
antigen load suggested by extra-pulmonary TB foci, lower
hemoglobin levels and shorter interval from ATT to ART were
all associated with paradoxical TB-IRIS in an univariate statistical
model. In multivariable analysis, a shorter interval from ATT to
ART and lower hemoglobin levels were independently associated
with IRIS. These data suggest that anemia from chronic infection
might be an important determinant of IRIS, but this needs to be
directly tested. Intriguingly, with the available sample size, there
was no association between lower CD4+ T-cell counts and higher
HIV RNA levels with increased risk of IRIS after adjustment for
confounding factors, including time interval from ATT to ART
initiation. One possibility is that the ATT alone caused an increase
in CD4+ T-cell counts pre-ART, and there was interaction
between these variables.
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The identification of plasma IL-6 and its downstream mediator
CRP as potential predictors of TB-IRIS is an important
observation considering the need for reliable easily performed
biomarkers to facilitate prevention or early interventions. A recent
retrospective case-control study in HIV+ patients demonstrated
that higher pre-ART plasma levels of IL-6, D-dimer and CRP are
associated with increased risk of AIDS events, IRIS or death [18].
Our results confirm that IL-6 and CRP are strongly associated
with paradoxical IRIS in the context of HIV/TB co-infection,
even after adjustment for other risk factors. Other studies assessing
predictors for IRIS in HIV+ patients with co-morbidities other
than TB (predominantly Pneumocystis jirovecii pneumonia with many
patients receiving corticosteroids at ART initiation) found
associations with another innate immune cytokine, IL-8, and
failed to show involvement of IL-6 [37], arguing that IL-6 might
play a more critical or specific role in mycobacterial IRIS. The
strong associations between IRIS and markers of inflammation
shown here reinforce the hypothesis that activation of myeloid cells
by mycobacterial associated molecular patterns [38] may play a
critical role in TB-IRIS pathogenesis [3,10].
The strengths of this study include the confirmation of
susceptible M. tuberculosis infection by culture positivity, as well as
the rigorous microbiologic and clinical follow up including
adherence supervision. This allowed us to rule out both
bacteriological and virological failure, drug resistance, noncom-
pliance and infection with non-tuberculous mycobacteria at the
time of diagnosis of IRIS. The limitations were that the study was
nested within a randomized controlled clinical trial with stringent
inclusion and exclusion criteria making the pool of candidate study
population smaller and possibly introducing a trial referral bias.
Nevertheless, the results were overall consistent with previous
observations and reinforce the contribution of severe immuno-
suppression and high antigen load to the onset of IRIS and the
potential role of CRP and IL-6 as predictors. Clinical and
laboratory predictors of IRIS in co-infected patients starting ART
such as those identified here may assist in anticipating complica-
tions and facilitate expeditious work up and clinical management.
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